This trial looks at how well tazemetostat works in treating patients with ovarian or endometrial cancer that has come back.
1 Primary · 5 Secondary · Reporting Duration: Up to 5 years
Experimental Treatment
86 Total Participants · 1 Treatment Group
Primary Treatment: Tazemetostat · No Placebo Group · Phase 2
Age 18+ · Female Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: